Puma Biotechnology Stock Today
| PBYI Stock | USD 6.59 0.38 6.12% |
PerformanceMild
| Odds Of DistressLow
|
Puma Biotechnology is trading at 6.59 as of the 4th of March 2026. This is a 6.12 percent increase since the beginning of the trading day. The stock's open price was 6.21. Puma Biotechnology has only a 6 % chance of going through financial distress over the next few years but had a somewhat mild performance during the last 90 days. The performance scores are derived for the period starting the 4th of December 2025 and ending today, the 4th of March 2026. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 24th of April 2012 | Category Healthcare | Classification Health Care |
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company was founded in 2010 and is headquartered in Los Angeles, California. The company has 50.39 M outstanding shares of which 3.66 M shares are at this time shorted by private and institutional investors with about 8.57 trading days to cover. More on Puma Biotechnology
Moving together with Puma Stock
Moving against Puma Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Puma Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Chairman | Alan Auerbach | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Ideas | (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, Dow Jones Biotechnology, NASDAQ Composite, NASDAQ Health Care, Biotech, Cancer Fighters, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsDebt leverage enables Puma Biotechnology to amplify potential investment gains using borrowed funds. Evaluating debt relative to total assets helps investors assess Puma Biotechnology's financial structure and understand the extent to which Puma Biotechnology's operations depend on creditor capital.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Puma Biotechnology (PBYI) is traded on NASDAQ Exchange in USA and employs 172 people. Puma Biotechnology is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 312.93 M. Puma Biotechnology conducts business under Biotechnology sector and is part of Health Care industry. The entity has 50.39 M outstanding shares of which 3.66 M shares are at this time shorted by private and institutional investors with about 8.57 trading days to cover.
Puma Biotechnology currently holds about 77.96 M in cash with 41.8 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.71.
Check Puma Biotechnology Probability Of Bankruptcy
Ownership AllocationPuma Biotechnology owns a total of 50.39 Million outstanding shares. The majority of Puma Biotechnology outstanding shares are owned by third-party entities. These institutional holders are usually referred to as non-private investors looking to secure positions in Puma Biotechnology to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Puma Biotechnology. Please pay attention to any change in the institutional holdings of Puma Biotechnology as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Puma Ownership Details
Puma Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| State Street Corp | 2025-09-30 | 748.7 K | |
| Comprehensive Portfolio Management, Llc | 2025-12-31 | 694 K | |
| Marshall Wace Asset Management Ltd | 2025-09-30 | 557.5 K | |
| Arrowstreet Capital Limited Partnership | 2025-12-31 | 547.9 K | |
| Northern Trust Corp | 2025-09-30 | 526.7 K | |
| Globeflex Capital, L.p. | 2025-12-31 | 452.6 K | |
| Lsv Asset Management | 2025-12-31 | 404.8 K | |
| D. E. Shaw & Co Lp | 2025-12-31 | 378.3 K | |
| Morgan Stanley - Brokerage Accounts | 2025-09-30 | 378.1 K | |
| Vanguard Group Inc | 2025-12-31 | 3.8 M | |
| Blackrock Inc | 2025-09-30 | 3.6 M |
Puma Biotechnology Historical Income Statement
Puma Stock Against Markets
Puma Biotechnology Corporate Management
| Jeffrey Ludwig | Chief Officer | Profile | |
| Roger Storms | Senior Sales | Profile | |
| Alvin Pharmd | Chief Officer | Profile | |
| Heather Blaber | Senior Marketing | Profile | |
| FRAPS BSc | Pharmacovigilance, Affairs | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Puma Biotechnology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in services. For more detail on how to invest in Puma Stock please use our How to Invest in Puma Biotechnology guide.You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Is there potential for Biotechnology market expansion? Will Puma introduce new products? Factors like these will boost the valuation of Puma Biotechnology. Anticipated expansion of Puma directly elevates investor willingness to pay premium valuations. Understanding fair value requires weighing current performance against future potential. All the valuation information about Puma Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.34) | Earnings Share 0.74 | Revenue Per Share | Quarterly Revenue Growth 0.277 | Return On Assets |
The market value of Puma Biotechnology is measured differently than its book value, which is the value of Puma that is recorded on the company's balance sheet. Investors also form their own opinion of Puma Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is Puma Biotechnology's true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Puma Biotechnology's market value can be influenced by many factors that don't directly affect Puma Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Puma Biotechnology's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Puma Biotechnology should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Puma Biotechnology's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.